Rapport Therapeutics Inc
NASDAQ:RAPP

Watchlist Manager
Rapport Therapeutics Inc Logo
Rapport Therapeutics Inc
NASDAQ:RAPP
Watchlist
Price: 30.76 USD 3.92% Market Closed
Market Cap: 1.5B USD

Relative Value

There is not enough data to reliably calculate the relative value of RAPP.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

RAPP Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
2.6
vs History
vs Industry
Median 3Y
-8.6
Median 5Y
-8.6
Industry
21.6
Forward
-10.7
vs History
vs Industry
Median 3Y
-10.9
Median 5Y
-10.9
Industry
16.5
vs History
vs Industry
Median 3Y
-10.3
Median 5Y
-10.3
Industry
22.5
vs History
0
vs Industry
Median 3Y
2.3
Median 5Y
2.3
Industry
2.3
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
2.9
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
5.5
vs History
vs Industry
Median 3Y
-4.9
Median 5Y
-4.9
Industry
13
Forward
-7.9
vs History
vs Industry
Median 3Y
-4.9
Median 5Y
-4.9
Industry
16.6
Forward
-7.9
vs History
vs Industry
Median 3Y
-6.4
Median 5Y
-6.4
Industry
15.8
vs History
vs Industry
Median 3Y
-6.1
Median 5Y
-6.1
Industry
19.1
vs History
25
vs Industry
Median 3Y
44.6
Median 5Y
44.6
Industry
1.9

Multiples Across Competitors

RAPP Competitors Multiples
Rapport Therapeutics Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Rapport Therapeutics Inc
NASDAQ:RAPP
1.5B USD 0 -15 -8.7 -8.7
US
Eli Lilly and Co
NYSE:LLY
997.2B USD 16.8 54.2 36.3 39
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
503.6B USD 5.5 20 16.4 21.3
CH
Roche Holding AG
SIX:ROG
255.1B CHF 4.1 27.1 11.6 13.5
UK
AstraZeneca PLC
LSE:AZN
209.4B GBP 4.8 29.9 108.6 158.9
CH
Novartis AG
SIX:NOVN
206.2B CHF 4.6 18 11.4 14.8
US
Merck & Co Inc
NYSE:MRK
244.4B USD 3.8 12.8 9.2 10.9
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK 4.4 13.2 9.3 10.8
IE
Endo International PLC
LSE:0Y5F
209B USD 90.1 -71.5 331.1 830.4
US
Pfizer Inc
NYSE:PFE
145.2B USD 2.3 14.8 7.5 10.3
P/E Multiple
Earnings Growth PEG
US
Rapport Therapeutics Inc
NASDAQ:RAPP
Average P/E: 23.8
Negative Multiple: -15
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
54.2
53%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
20
29%
0.7
CH
Roche Holding AG
SIX:ROG
27.1
29%
0.9
UK
AstraZeneca PLC
LSE:AZN
29.9
38%
0.8
CH
Novartis AG
SIX:NOVN
18
17%
1.1
US
Merck & Co Inc
NYSE:MRK
12.8
15%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
13.2
4%
3.3
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -71.5 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.8
29%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Rapport Therapeutics Inc
NASDAQ:RAPP
Average EV/EBITDA: 438.8
Negative Multiple: -8.7
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
36.3
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.4
9%
1.8
CH
Roche Holding AG
SIX:ROG
11.6
4%
2.9
UK
AstraZeneca PLC
LSE:AZN
108.6
10%
10.9
CH
Novartis AG
SIX:NOVN
11.4
6%
1.9
US
Merck & Co Inc
NYSE:MRK
9.2
6%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
9.3
2%
4.6
IE
E
Endo International PLC
LSE:0Y5F
331.1
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
1%
7.5
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Rapport Therapeutics Inc
NASDAQ:RAPP
Average EV/EBIT: 1 881.2
Negative Multiple: -8.7
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
39
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
21.3
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.5
5%
2.7
UK
AstraZeneca PLC
LSE:AZN
158.9
23%
6.9
CH
Novartis AG
SIX:NOVN
14.8
12%
1.2
US
Merck & Co Inc
NYSE:MRK
10.9
8%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
10.8
1%
10.8
IE
E
Endo International PLC
LSE:0Y5F
830.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.3
8%
1.3